8 Results for "

Lung-targeted

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "Lung-targeted" in MCE Product Catalog:

Cat. No.: HY-P5423
CAS No.: 107658-43-5
Target:  

Exosomes Liposome

Research Areas:  

Cancer

GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems .
loading...
    loading...
Cat. No.: HY-150229
CAS No.: 2803699-70-7
Purity:  98.84%
Target:  

Liposome

Research Areas:  

Cancer

306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
loading...
    loading...
Cat. No.: HY-125019
CAS No.: 1831144-46-7
Purity:  99.86%
Target:  

JAK STAT

Research Areas:  

Inflammation/Immunology

iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .
loading...
    loading...
Cat. No.: HY-P2548
CAS No.: 176042-83-4
Target:  

EGFR

Research Areas:  

Others

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .
loading...
    loading...
Cat. No.: HY-172329
CAS No.: 3112713-48-8
Target:  

Liposome

Research Areas:  

Others

Q1-ALC-0315 iodide is a cationic quaternary ammonium lipid derivative of the ionizable cationic lipid ALC-0315 (HY-138170). Q1-ALC-0315-based LNPs can be used for lung-targeted mRNA delivery, which demonstrates high-performing firefly luciferase protein expression in the lungs .
loading...
    loading...
Cat. No.: HY-K2025

MCE In vivo OptiLNP RNA Transfection Reagent (Lung-targeted) is a ready-to-use transfection reagent based on LNP technology. It is designed for the efficient transfection of mRNA and short-chain RNA via intravenous injection in experimental animals.

loading...
    loading...
Cat. No.: HY-171784
CAS No.: 2832061-40-0
Target:  

Liposome

Research Areas:  

Cancer

Lipid PPz-2R1 is a lung-targeted lipid. Lipid PPz-2R1 is formulated into lipid nanoparticles (LNPs) for mRNA delivery. Lipid PPz-2R1 can be used for in situ lung cancer research .
loading...
    loading...
Cat. No.: HY-184535
CAS No.: 3008320-14-4
PDIC-DPC is a HMGA1 inhibitor and lung-targeting agent. PDIC-DPC upregulates STING expression and enhances STING-mediated immune signaling. PDIC-DPC inhibits the TGFβ-Smad pathway and activates AMPK. PDIC-DPC forms nanocomplexes with fibrinogen β chain and vitronectin, and achieves lung-specific accumulation by binding to pulmonary endothelial receptors. PDIC-DPC reverses established pulmonary fibrosis, reduces collagen deposition, restores alveolar structure, improves pulmonary function, and inhibits in situ ESCC growth. PDIC-DPC can be used for the research of esophageal squamous cell carcinoma and idiopathic pulmonary fibrosis .
loading...
    loading...